research 5α-Reductase Inhibitors (5ARIs) and Male Reproduction
5α-Reductase inhibitors can negatively affect male sexual function and, in some cases, significantly reduce sperm count, but these effects may be reversible.
Search
for
Sort by
Research
30 / 1000+ results 
research PCPT, MTOPS and the use of 5ARIs: a Canadian consensus regarding implications for clinical practice
5ARIs like finasteride can help prevent prostate cancer and treat BPH, but guidelines should be updated to reflect this.
research The Risk of Venous Thromboembolism (VTE) in Men with Benign Prostatic Hyperplasia Treated with 5-Alpha Reductase Inhibitors (5ARIs).
Men using 5-alpha reductase inhibitors for prostate issues may have a slightly higher risk of blood clots.
research 5ARIs and PSA: Evidences
5ARIs lower PSA levels, but other tests are needed to avoid missing aggressive prostate cancer.
research Comments concerning the real risk of sexual adverse events secondary to the use of 5-ARIs
The document concludes that the risk of sexual side effects from 5-alpha-reductase inhibitors is low and often temporary, but more research is needed on potential permanent effects.
research Sponsored Lecture 3 : Updates on 5 alpha-rers(5ARIs) for the treatment of male pattern hair loss(MPHL)
5AR inhibitors like finasteride and dutasteride improve hair growth and slow hair loss in male pattern baldness.
research Long-term use of 5α-reductase inhibitors and the risk of male breast cancer
Taking 5α-reductase inhibitors does not significantly increase the risk of breast cancer in men.
research A population‐based nested case–control study: the use of 5‐alpha‐reductase inhibitors and the increased risk of osteoporosis diagnosis in patients with benign prostate hyperplasia
Taking finasteride for benign prostate hyperplasia may increase the risk of osteoporosis, especially at higher doses.
research Bladder Cancer Survival of Men Receiving 5α-Reductase Inhibitors
Men taking 5-alpha-reductase inhibitors before or after bladder cancer diagnosis had a lower risk of dying from the disease.
research 5‐Alpha reductase inhibitors in androgenetic alopecia: Shifting paradigms, current concepts, comparative efficacy, and safety
Dutasteride works better than finasteride for hair loss, with both being safe to use.
research Sexual Dysfunction Related to Drugs: a Critical Review. Part V: α-Blocker and 5-ARI Drugs
α-Blockers and 5-ARIs for BPH can cause sexual dysfunction, including erectile and ejaculatory issues.
research Impact of Alpha Blockers, 5-alpha Reductase Inhibitors and Combination Therapy on Sexual Function
Medications for enlarged prostate can cause sexual side effects like reduced libido, erectile dysfunction, and ejaculatory problems.
research Sexual Problems of Men With Androgenic Alopecia Treated With 5-Alpha Reductase Inhibitors
Men using hair loss drugs like finasteride may experience sexual side effects like erectile dysfunction, but it's unclear who will be affected and when. Treating depression and sexual symptoms is suggested, as these men often have higher rates of both. More research is needed to understand why these side effects occur.
research Receipt of 5-Alpha Reductase Inhibitors Before Radical Cystectomy: Do They Render High-Grade Bladder Tumors Less Aggressive?
Taking 5-Alpha Reductase Inhibitors before bladder removal surgery might make high-grade bladder tumors less aggressive.
research 5-Alpha Reductase Inhibitors in Prostate Cancer: From Clinical Trials to Clinical Practice
5-Alpha reductase inhibitors may prevent prostate cancer but are not widely used due to concerns about trial relevance and potential risks, and more research is needed to confirm long-term benefits.
research Macular Abnormalities Associated With 5α-Reductase Inhibitor
Using 5-alpha-reductase inhibitors, drugs for prostate issues and hair loss, may lead to eye abnormalities in men.
research Three Considerations Before Advising 5-α-Reductase Inhibitors for Chemoprevention
5-α-reductase inhibitors don't prevent prostate cancer but may reduce unnecessary biopsies.
research Effects of 5‐alpha reductase inhibitors on lung function: A reason for discontinuation duringCOVID ‐19 pandemic?
5-alpha reductase inhibitors might worsen lung recovery in COVID-19 patients, suggesting a pause in their use.
research The connection of 5-alpha reductase inhibitors to the development of depression
5-alpha reductase inhibitors, like finasteride and dutasteride, may cause depression, but more research is needed to understand why.
research Bladder cancer survival in men using 5-alpha-reductase inhibitors
Using 5-alpha-reductase inhibitors may improve bladder cancer survival in men.
research The Effects of Oral 5-alpha Reductase Inhibitors on Penile Intracavernosal Pressures and Penile Morphology in Rat Model.
Oral finasteride and dutasteride may negatively affect erectile function in rats.
research Re: Risk of Erectile Dysfunction Associated with Use of 5α-Reductase Inhibitors for Benign Prostatic Hyperplasia or Alopecia: Population Based Studies Using the Clinical Practice Research Datalink
Using finasteride for hair loss or prostate issues does not significantly raise the risk of erectile dysfunction.
research The role of 5-alpha-reductase inhibitors in active surveillance
5-alpha-reductase inhibitors might help slow down low-risk prostate cancer, but their use should be cautious.
research Association Between 5α-Reductase Inhibitors and Prostate Cancer Mortality
5α-reductase inhibitors may help with prostate cancer but could increase the risk of severe tumors, so careful use is advised.
research 5-Alpha Reductase Inhibitor Use and Prostate Cancer Prevention: A Victim of the Times?
5-Alpha reductase inhibitors are safe long-term but may be outdated for preventing less significant prostate cancer.
research SÍNDROME PÓS-FINASTERIDA E O IMPACTO DOS INIBIDORES DA 5-ALFA REDUTASE NOS EIXOS NEUROENDÓCRINO E METABÓLICO
This review analyzes recent scientific evidence on the neuroendocrine and metabolic impacts of chronic use of 5-alpha reductase inhibitors, focusing on Post-Finasteride Syndrome (PFS). The study, based on eight high-impact studies from 2021 to 2026, highlights PFS as a multisystemic condition linked to the use of 5-ARIs, with reports of refractory sexual dysfunction and mood disorders in young patients. The inhibition of enzymes in the central nervous system suppresses the synthesis of active metabolites like allopregnanolone, leading to GABAergic dysregulation and excitotoxicity. Metabolically, the suppression of dihydrotestosterone is associated with insulin resistance, non-alcoholic fatty liver disease, Type 2 Diabetes Mellitus, and changes in gut microbiota. Genetic polymorphisms in the SRD5A2 gene and epigenetic changes, such as DNA methylation of the androgen receptor, contribute to the chronicity of symptoms. The findings suggest that PFS extends beyond transient side effects, emphasizing the need for personalized medicine models and strengthened informed consent protocols to mitigate persistent biopsychosocial risks.
research Depression risk of 5-alpha reductase inhibitors: impact of active-comparator versus non-drug user control groups on risk measurement
This meta-analysis examined the risk of depression associated with 5-alpha reductase inhibitors (5-ARIs) across 5 longitudinal studies involving 2,517,859 patients. The findings indicate a 31% increased risk of depression with 5-ARI use, though this risk varies significantly depending on the control group used. Studies with non-drug controls reported a higher risk, while those with alpha-blocker comparators showed a decreased risk. The choice of comparator group was a major source of heterogeneity in the results. Overall, the risk of depression with 5-ARI use is likely minimal, with observational data suggesting a slight reduction in risk and randomized data indicating a potential slight increase. Previous reports of a much higher risk may have resulted from inappropriate control group selection.
research Reduced Prostate Cancer Risk in Patients with Androgenetic Alopecia Using 5-Alpha Reductase Inhibitors: A TriNetX Real-World Cohort Study
Using 5-alpha reductase inhibitors may lower prostate cancer risk in people with androgenetic alopecia.
research Supplementary Material for: Drug-Induced Melasma in Patients on 5-Alpha Reductase Inhibitors: A Case Report
Finasteride can cause melasma, especially in people with darker skin.
research Supplementary Material for: Drug-Induced Melasma in Patients on 5-Alpha Reductase Inhibitors: A Case Report
Finasteride can cause melasma, especially in people with darker skin.